Par Pharmaceutical resizes generic unit
This initiative will enable Par to more effectively optimize its current product portfolio and its pipeline of first-to-file/first-to-market products. As a result, the company believes it will be
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).